<p>加拿大温哥華，2026 年 5 月 18 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（納斯達克：CMND）（“Clearmind” 或 “公司”）是一家臨牀階段的生物技術公司，專注於發現和開發新型非致幻的第二代神經塑性藥物，以解決主要的未充分治療的健康問題。今天，公司宣佈與耶路撒冷希伯來大學的 Yissum 研究發展公司簽署了一項新的研究協議。該協議將資助一項全面的臨牀前研究，評估 MEAI（CMND-100）的代謝療效，包括與 tirzepatide 治療結合使用及作為飲食誘導肥胖（“DIO”）小鼠的維持治療。該研究將由耶路撒冷希伯來大學藥物研究所藥學院的 Joseph（Yossi）Tam 教授及其團隊進行。</p>
<p>基於胰高血糖素樣肽的療法和 tirzepatide 的全球市場已經發展成為一個龐大的產業，預計在 2025 年價值約為 500 億至 660 億美元，並預計到 2033 年將達到 1700 億至 1850 億美元。這些療法顯著推動了肥胖和 2 型糖尿病的治療，帶來了顯著的體重減輕和心代謝改善。儘管取得了顯著成功，GLP-1 和雙重 GLP-1/GIP 受體激動劑主要通過抑制食慾和減少能量攝入來發揮作用。一個主要的臨牀挑戰仍然存在：在停藥後，通常會出現顯著的體重反彈——往往在一年內恢復失去體重的 25% 或更多，同時代謝益處也會部分逆轉。這突顯了迫切需要補充或維持策略，以增強治療的持久性，幫助保持瘦體重，並積極提高能量消耗。</p>
<p>在與耶路撒冷希伯來大學 Yossi Tam 教授實驗室的先前合作中，MEAI 在 DIO 小鼠中顯示出約 15% 至 20% 的體重減輕，主要通過增加能量消耗和脂肪利用，同時保持瘦體重並改善葡萄糖穩態和肝脂肪變性，Clearmind 現在正在推進 MEAI 與當今領先的胰高血糖素療法的組合和序列策略。</p>
<p>新的為期 12 個月的研究，題為 “評估 MEAI 與 tirzepatide 聯合和序列使用在飲食誘導肥胖小鼠中的代謝療效”，將研究：MEAI 與 tirzepatide 同時給藥時的附加或協同效應，以及 MEAI 作為維持治療以減輕停用 tirzepatide 後的體重反彈和保持代謝益處的潛力，涵蓋多個劑量。</p>
<p>“MEAI 旨在提供一種差異化的機制，可能補充胰高血糖素療法，” Clearmind Medicine 首席執行官 Adi Zuloff-Shani 博士表示。“雖然這些藥物在減少食物攝入方面表現出色，但我們之前的臨牀前數據表明，MEAI 顯著增強了能量消耗。我們相信，這種組合和維持的方法有潛力為患者提供更強大、持久和臨牀上有意義的結果。”</p>
<p><strong>關於 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家臨牀階段的神經塑性藥物生物技術公司，專注於發現和開發非致幻的第二代神經塑性藥物，以解決廣泛且未得到充分服務的健康問題，包括酒精使用障礙。其主要目標是研究和開發基於迷幻藥的化合物，並嘗試將其商業化為受監管的藥物、食品或補充劑。</p>
<p>公司的知識產權組合目前包括十九個專利系列，其中包括 31 項已授予的專利。公司打算在必要時為其化合物申請額外的專利，並將保持機會主義，以獲取更多知識產權以擴展其組合。</p>
<p>Clearmind 的股票在納斯達克上市，股票代碼為 “CMND”。</p>
<p>欲瞭解更多信息，請訪問：https://www.clearmindmedicine.com 或聯繫：</p>
<p>投資者關係</p>
<p>invest@clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性聲明：</strong></p>
<p>本新聞稿包含《私人證券訴訟改革法案》和其他證券法意義上的 “前瞻性聲明”。諸如 “預計”、“預期”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語或類似表達及其變體旨在識別前瞻性聲明。例如，當公司討論全球基於胰高血糖素樣肽療法市場的預期增長、Clearmind 如何將 MEAI 推進到與當前領先的胰高血糖素樣肽療法的組合和序列策略時，MEAI 被設計為提供一種可能補充胰高血糖素樣肽療法的差異化機制，並且公司相信 MEAI 與胰高血糖素樣肽療法的組合和維持方法有潛力為患者提供更強大、持久和具有臨牀意義的結果時，便使用了前瞻性聲明。前瞻性聲明不是歷史事實，而是基於管理層當前的期望、信念和預測，其中許多本質上具有不確定性。這些期望、信念和預測是以善意表達的。然而，無法保證管理層的期望、信念和預測將會實現，實際結果可能與前瞻性聲明中所表達或指示的內容有實質性差異。前瞻性聲明受到風險和不確定性的影響，這可能導致實際表現或結果與前瞻性聲明中所表達的內容有實質性差異。有關影響公司的風險和不確定性的更詳細描述，請參考公司不時向證券交易委員會（“SEC”）提交的報告，包括但不限於公司截至 2025 年 10 月 31 日的財政年度的 20-F 表格年報中詳細列出的風險及隨後向 SEC 提交的文件。前瞻性聲明僅在聲明發布之日有效。公司不承擔更新前瞻性聲明以反映實際結果、後續事件或情況、假設變化或影響前瞻性信息的其他因素變化的義務，除非適用的證券法要求。如果公司更新一項或多項前瞻性聲明，不應推斷公司將就此或其他前瞻性聲明進行額外更新。提供的參考和鏈接僅為方便，網站上包含的信息不被納入本新聞稿的引用。Clearmind 對第三方網站的內容不承擔責任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qRXdNU00zTmpBNE5URTJJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qRXdNU00zTmpBNE5URTJJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

禮來

<p>Clearmind Medicine Inc. 已與 Yissum Research Development Company 簽署了一項研究協議，旨在研究 MEAI 與 tirzepatide 聯合使用在飲食誘導肥胖小鼠中的代謝療效。為期 12 個月的研究旨在評估 MEAI 作為維持治療的潛力，以防止在 tirzepatide 治療後體重反彈。Clearmind 的首席執行官 Adi Zuloff-Shani 博士認為，這種組合可能增強治療的持久性並改善患者的治療效果</p>

<p>Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the signing of a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. The agreement will fund a comprehensive preclinical study evaluating the metabolic efficacy of MEAI (CMND-100), both in combination with and as a maintenance therapy following tirzepatide treatment in diet-induced obese (&#34;DIO&#34;) mice. The research will be conducted by Professor Joseph (Yossi) Tam and his team at the Obesity and Metabolism Laboratory at the Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem.</p>
<div class="lb-trans"><p>加拿大温哥華，2026 年 5 月 18 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（納斯達克：CMND）（“Clearmind” 或 “公司”）是一家臨牀階段的生物技術公司，專注於發現和開發新型非致幻的第二代神經塑性藥物，以解決主要的未充分治療的健康問題。今天，公司宣佈與耶路撒冷希伯來大學的 Yissum 研究發展公司簽署了一項新的研究協議。該協議將資助一項全面的臨牀前研究，評估 MEAI（CMND-100）的代謝療效，包括與 tirzepatide 治療結合使用及作為飲食誘導肥胖（“DIO”）小鼠的維持治療。該研究將由耶路撒冷希伯來大學藥物研究所藥學院的 Joseph（Yossi）Tam 教授及其團隊進行。</p>
</div><p>The global market for incretin-based therapies and tirzepatide has grown into a massive industry valued at approximately $50–66 billion in 2025, and is projected to reach $170–185 billion by 2033. These therapies have significantly advanced the treatment of obesity and type 2 diabetes, delivering substantial weight loss and cardiometabolic improvements. Despite their remarkable success, GLP-1 and dual GLP-1/GIP receptor agonists primarily work by suppressing appetite and reducing energy intake. A major clinical challenge remains: substantial weight regain- often 25% or more of the lost weight within one year, along with partial reversal of metabolic benefits, frequently occurs upon discontinuation. This underscores the urgent need for complementary or maintenance strategies that can enhance treatment durability, help preserve lean muscle mass, and actively boost energy expenditure.</p>
<div class="lb-trans"><p>基於胰高血糖素樣肽的療法和 tirzepatide 的全球市場已經發展成為一個龐大的產業，預計在 2025 年價值約為 500 億至 660 億美元，並預計到 2033 年將達到 1700 億至 1850 億美元。這些療法顯著推動了肥胖和 2 型糖尿病的治療，帶來了顯著的體重減輕和心代謝改善。儘管取得了顯著成功，GLP-1 和雙重 GLP-1/GIP 受體激動劑主要通過抑制食慾和減少能量攝入來發揮作用。一個主要的臨牀挑戰仍然存在：在停藥後，通常會出現顯著的體重反彈——往往在一年內恢復失去體重的 25% 或更多，同時代謝益處也會部分逆轉。這突顯了迫切需要補充或維持策略，以增強治療的持久性，幫助保持瘦體重，並積極提高能量消耗。</p>
</div><p>Building on positive results from its prior collaboration with Professor Yossi Tam’s laboratory at the Hebrew University, where MEAI demonstrated approximately 15–20% body weight reduction in DIO mice, primarily through increased energy expenditure and fat utilization while preserving lean mass and improving glucose homeostasis and hepatic steatosis, Clearmind is now advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy.</p>
<div class="lb-trans"><p>在與耶路撒冷希伯來大學 Yossi Tam 教授實驗室的先前合作中，MEAI 在 DIO 小鼠中顯示出約 15% 至 20% 的體重減輕，主要通過增加能量消耗和脂肪利用，同時保持瘦體重並改善葡萄糖穩態和肝脂肪變性，Clearmind 現在正在推進 MEAI 與當今領先的胰高血糖素療法的組合和序列策略。</p>
</div><p>The new 12-month study, titled “Assessing the Metabolic Efficacy of MEAI in Combination and Sequencing with Tirzepatide in Diet-Induced Obese Mice,” will examine: Additive or synergistic effects when MEAI is administered concomitantly with tirzepatide and the potential of MEAI as a maintenance therapy to attenuate post-tirzepatide weight regain and preserve metabolic benefits across multiple doses.</p>
<div class="lb-trans"><p>新的為期 12 個月的研究，題為 “評估 MEAI 與 tirzepatide 聯合和序列使用在飲食誘導肥胖小鼠中的代謝療效”，將研究：MEAI 與 tirzepatide 同時給藥時的附加或協同效應，以及 MEAI 作為維持治療以減輕停用 tirzepatide 後的體重反彈和保持代謝益處的潛力，涵蓋多個劑量。</p>
</div><p>“MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies,” said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. “While those drugs excel at reducing food intake, our previous preclinical data show MEAI significantly enhances energy expenditure. We believe that this combination and maintenance approach has potential to deliver more robust, durable, and clinically meaningful outcomes for patients.”</p>
<div class="lb-trans"><p>“MEAI 旨在提供一種差異化的機制，可能補充胰高血糖素療法，” Clearmind Medicine 首席執行官 Adi Zuloff-Shani 博士表示。“雖然這些藥物在減少食物攝入方面表現出色，但我們之前的臨牀前數據表明，MEAI 顯著增強了能量消耗。我們相信，這種組合和維持的方法有潛力為患者提供更強大、持久和臨牀上有意義的結果。”</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家臨牀階段的神經塑性藥物生物技術公司，專注於發現和開發非致幻的第二代神經塑性藥物，以解決廣泛且未得到充分服務的健康問題，包括酒精使用障礙。其主要目標是研究和開發基於迷幻藥的化合物，並嘗試將其商業化為受監管的藥物、食品或補充劑。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知識產權組合目前包括十九個專利系列，其中包括 31 項已授予的專利。公司打算在必要時為其化合物申請額外的專利，並將保持機會主義，以獲取更多知識產權以擴展其組合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND.&#34;</p>
<div class="lb-trans"><p>Clearmind 的股票在納斯達克上市，股票代碼為 “CMND”。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問：https://www.clearmindmedicine.com 或聯繫：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for incretin-based therapies, how Clearmind is advancing MEAI into combination and sequencing strategies with today’s leading incretin therapy, how MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies and its belief that the combination and maintenance approach of MEAI and incretin therapies has potential to deliver more robust, durable, and clinically meaningful outcomes for patients. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新聞稿包含《私人證券訴訟改革法案》和其他證券法意義上的 “前瞻性聲明”。諸如 “預計”、“預期”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語或類似表達及其變體旨在識別前瞻性聲明。例如，當公司討論全球基於胰高血糖素樣肽療法市場的預期增長、Clearmind 如何將 MEAI 推進到與當前領先的胰高血糖素樣肽療法的組合和序列策略時，MEAI 被設計為提供一種可能補充胰高血糖素樣肽療法的差異化機制，並且公司相信 MEAI 與胰高血糖素樣肽療法的組合和維持方法有潛力為患者提供更強大、持久和具有臨牀意義的結果時，便使用了前瞻性聲明。前瞻性聲明不是歷史事實，而是基於管理層當前的期望、信念和預測，其中許多本質上具有不確定性。這些期望、信念和預測是以善意表達的。然而，無法保證管理層的期望、信念和預測將會實現，實際結果可能與前瞻性聲明中所表達或指示的內容有實質性差異。前瞻性聲明受到風險和不確定性的影響，這可能導致實際表現或結果與前瞻性聲明中所表達的內容有實質性差異。有關影響公司的風險和不確定性的更詳細描述，請參考公司不時向證券交易委員會（“SEC”）提交的報告，包括但不限於公司截至 2025 年 10 月 31 日的財政年度的 20-F 表格年報中詳細列出的風險及隨後向 SEC 提交的文件。前瞻性聲明僅在聲明發布之日有效。公司不承擔更新前瞻性聲明以反映實際結果、後續事件或情況、假設變化或影響前瞻性信息的其他因素變化的義務，除非適用的證券法要求。如果公司更新一項或多項前瞻性聲明，不應推斷公司將就此或其他前瞻性聲明進行額外更新。提供的參考和鏈接僅為方便，網站上包含的信息不被納入本新聞稿的引用。Clearmind 對第三方網站的內容不承擔責任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qRXdNU00zTmpBNE5URTJJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMjEwMSM3NjA4NTE2IzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YjljNzQyZTItYWUwNy00MmY0LWI5MWItNGZlZDNlMTVjYzEzLTUwMDA4NjkzNC0yMDI2LTA1LTE4LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications | CMND Stock News

Clearmind Medicine 簽署協議，研究 MEAI 與 Tirzepatide 的組合及排序，以對抗重磅 GLP-1 藥物 | CMND 股票新聞